14 The past two decades have brought many important advances in our understanding of the 15 hereditary susceptibility to cancer. Numerous studies have provided convincing evidence that 16 identification of germline mutations associated with hereditary cancer syndromes can lead to 17 reductions in morbidity and mortality through targeted risk management options. Additionally, 18 advances in gene sequencing technology now permit the development of multigene hereditary 19 cancer testing panels. Here, we describe the 2016 revision of the Counsyl Inherited Cancer 20 Screen for detecting single-nucleotide variants (SNVs), short insertions and deletions (indels), 21 and copy number variants (CNVs) in 36 genes associated with an elevated risk for breast, 22 ovarian, colorectal, gastric, endometrial, pancreatic, thyroid, prostate, melanoma, and 23 neuroendocrine cancers. To determine test accuracy and reproducibility, we performed a 24 rigorous analytical validation across 341 samples, including 118 cell lines and 223 patient 25 samples. The screen achieved 100% test sensitivity across different mutation types, with high 26 specificity and 100% concordance with conventional Sanger sequencing and multiplex ligation-27 dependent probe amplification (MLPA). We also demonstrated the screen's high intra-run and 28 inter-run reproducibility and robust performance on blood and saliva specimens. Furthermore, 29 we showed that pathogenic Alu element insertions can be accurately detected by our test. 30 Overall, the validation in our clinical laboratory demonstrated the analytical performance 31 required for collecting and reporting genetic information related to risk of developing hereditary 32 cancers. 33 34 Datasets for this article are available online (10.5281/zenodo.193264). 35 42 options. For example, for unaffected women who carry a BRCA1 or BRCA2 mutation, risk-43 reducing salpingo-oophorectomy results in a significant reduction in all-cause mortality (3% vs. 44 10%; hazard ratio [HR] 0.40; 95% CI, 0.26-0.6), breast cancer-specific mortality (2% vs. 6%; 45 HR 0.44; 95% CI, 0.26-0.76) and ovarian cancer-specific mortality (0.4 vs. 3%; HR 0.21; 95% 46 CI, 0.
INTRODUCTION 36
Tremendous advances in our knowledge of evaluating and treating patients with germline 37 mutations associated with hereditary cancer syndromes have been realized in the past two 38
decades. Multiple studies demonstrate the feasibility and clinical utility of genetic testing 39 (Norton et importantly, studies have provided convincing evidence that identification of hereditary cancer 41 syndromes can lead to reductions in morbidity and mortality through targeted risk management the American College of Medical Genetics and Genomics (ACMG) guidelines for analytical 82 validation of NGS methods . The validation study included both well-83 characterized cell lines (N=118) and de-identified patient samples (N=223) with clinically 84 relevant variants. 85 86 MATERIALS AND METHODS 87
Institutional Review Board Approval 88
The protocol for this study was approved by Western Institutional Review Board (IRB number 89 1145639) and complied with the Health Insurance Portability and Accountability Act (HIPAA). 90
The information associated with patient samples was de-identified in accordance with the 91 HIPAA Privacy Rule. A waiver of informed consent was requested and approved by the IRB. Table S1 . 103 104
The selected genes are tested for SNVs, indels, and CNVs throughout coding exons and 20 bp of 105 flanking intronic sequences. Additionally, known deleterious variants outside the coding regions 106 are sequenced. In EPCAM, only large deletions that include exon 9 are reported as these 107
mutations are known to silence the MSH2 gene (Tutlewska, Lubinski, and Kurzawski, 2013) . In 108 GREM1, specific pathogenic duplications in the promoter, which are commonly associated with 109 individuals of Ashkenazi Jewish descent, are covered. Specifically, the screen targets the three 110 most common promoter duplications in GREM1 (coordinates with respect to GRCh37/hg19 111 reference assembly): 112
• chr15:32,964,939-33,004,759 (40kb) 113
• chr15:32,986,220-33,002,449 (16kb) 114
• chr15:32,975,886-33,033,276 (57kb) 115
For PMS2, exons 11-15 are excluded from the reportable region of interest (ROI) because of 116 high similarity between this portion of PMS2 and its highly homologous pseudogene PMS2CL. 117
In RET, exon 1 is not sequenced due to high guanine-cytosine (GC) content. 118 119
Next Generation DNA Sequencing 120
Our application of next-generation DNA sequencing is performed as described previously ( at that position, we construct a statistical model for the likelihood of observing a given number 148 of mapped reads !,! at a given genomic position for sample with copy number !,! . 149 150
The expected number of reads is dependent upon 3 factors: the average depth for that targeted 151 location across samples ! , the average depth for that particular sample across targeted positions 152 ! , and the local copy number of the sample's genome at that targeted position. These are first 153 determined by finding the median depth at targeted region across all ! samples in an analyzed 154 flowcell lane 155
then the sample dependent factor ! is found by taking the median across all ! positions in 156 genome after normalizing for the expected number of reads at each position 157
Combining these factors the observed data are modeled by the negative binomial distribution 158
This characterization has been found to accurately model the observed number of reads from 160 previous targeted sequencing experiments (Anders & Huber, 2010) . 161 162
In the negative binomial model, the variance parameter ! accounts for regions of the genome 163
where sequencing depth is observed to follow idealized Poisson statistics in the limit that → ∞ 164
and regions that are excessively noisy with respect to observed number of reads when → 0. 165 ! may be estimated as 166
which is found to closely model the empirical distribution over several orders of magnitude in 167 read depth. 168 169
Because duplications and deletions will simultaneously impact the expected depth of all genomic 170 positions encompassing the variant, depth data from spatially adjacent positions are correlated. 171
We leverage the HMM to account for this correlation. The HMM's state transition probabilities 172 between wild-type and copy-number-variant are parameterized by matching the average length 173 of such variations observed in human population (Sudmant et. al. 2015 ) through setting 174 !"#→!" = 1/6200 between each subsequent base-pair and a prior on the frequency of such 175 variations 176 177
The prior !"# = 0.001 was determined by balancing the thresholds for confident calling and 179
retesting of calls to achieve the desired sensitivity and specificity, and the prior was set 180
independently of this validation. 181 182
Detecting CNVs using this probabilistic framework invokes the Viterbi algorithm (Korn et. al., 183 2008) to determine the most likely number of copies at every targeted region within a sample. 184
Any contiguous regions of duplication or deletion produce a reported variant, and the confidence 185 of that call is determined by aggregating the posterior probability of the call 186 !"#$% ( !,! ≠ 2) not being wildtype over the called region. 187 188
All copy-number called variants are inspected for quality of raw data by human review, and 189
observed positive variants are rerun in our production SOP for verification of the call. Samples 190 that emit low confidence called variants are additionally rerun to resolve a confident genotype.
192
Detection of Alu Insertions 193
Alu positives were detected by looking for Alu sequences in reads overlapping with Alu 194 insertion positions. All insertions were only tested for at positions where the sequence had been 195 previously confirmed by Sanger sequencing. At the site of an Alu insertion, the Alu sequence is 196 soft-clipped by BWA alignment. These soft-clipped reads were compiled; duplicate reads were 197 discarded; and the remaining reads with sequences matching the known Alu sequence at this site 198
were tallied. Sites with three unique reads matching the Alu sequence were called as Alu 199
positive.
201
Pre-and Post-sequencing Quality Metrics 202
To ensure the quality of the results obtained from the assay, 27 different review checkpoints 203 (Table S2) were censored from the analysis. As no-calls have the potential to introduce clinically relevant 230 false negatives, we separately examined the no-calls containing potentially deleterious alleles by 231 treating no-calls as homozygous reference and comparing to the 1000 Genomes calls. We found 232 all no-calls when treated as homozygous reference were concordant with the exception that one 233 comparison was inconclusive due to low allele balance in both our data and the exome data from 234 the 1000 Genomes Project (Table S8) . sequencing was used for orthogonal confirmation; MLPA analysis of this sample failed to 325 identify the partial deletion of exon 15 in APC because the deletion was relatively small and fell 326 between the MLPA probes (Table S4b) . For the patient sample Counsyl_128, two duplications 327 affecting exons 8-9 of EPCAM and exons 1-16 of MSH2 were detected and confirmed by MLPA. 328
Additionally, 5 NIBSC reference samples with known CNVs in the MLH1 and MSH2 genes 329
were included in the validation. Among the 49 tested samples (a total of 50 CNVs), 12 had a 330 single-exon deletion or duplication, which can be technically challenging for a NGS-based assay 331 (Table 3) . 332
As shown in Table 5 , we detected all 50 CNVs, including 12 single-exon events, 333
demonstrating the high sensitivity of the assay (100%; 95% CI, 100%-93%). Furthermore, no 334 additional CNV calls were made in the 49 sample cohort, resulting in 100% specificity (Table 5) .
336
Challenging indels 337
To measure accuracy for detecting indels, we built a cohort (N=82) of patient samples with 338 variants of a range of sizes, including both short (<10bp) and the more technically challenging 339 long (>10bp) deletions or insertions (Tables 3 and S6a ). These samples were identified using a 340 previous version of the Counsyl test (a 24-gene panel) and orthogonally confirmed by Sanger.
341
We then tested these samples with the newly developed 36-gene panel and confirmed all of the 342 expected indel calls; no false-positives nor false-negatives were observed in the 36-gene panel 343
results (Table 5) validation study (Table 6 ). We confirmed that the Alu insertions identified by the Counsyl 356
Inherited Cancer Screen were also detected by Sanger sequencing.
358
Reproducibility 359
In addition to establishing the test's analytical sensitivity and specificity, Counsyl's Inherited 360
Cancer Screen was validated for intra-and inter-run call reproducibility. Intra-run reproducibility 361 of SNV and indel calls was established by testing 8 cell lines and 13 blood or saliva samples in 362 2-3 replicates in the same batch, split across sequencer lanes. Inter-run reproducibility was 363 validated by testing 8 cell lines and 84 patient blood or saliva samples in 2-3 different batches 364 (Table S7a ). Concordance between replicates was > 99.99%, with just one discordant call at a 365 known benign homopolymer site in an intron of ATM (Table S7a) . 366
For CNVs, intra-run and inter-run reproducibility was established using the Coriell 367 sample NA14626 with a duplication of BRCA1 exon 12 ( The high accuracy reported here underlines the importance of using metrics beyond 415 simple base and variant call quality to assess NGS variant calls. Table S2 shows the 416 comprehensive set of metrics by which we assess each variant call. As one example, information 417 on read directionality ("strand bias LOD") is incorporated into our pipeline, and would have 418 eliminated many of the false positives encountered by Mu et al (in particular, the MSH2 419 homopolymer site) without sacrificing sensitivity. Finally, the call review process described here 420
includes visual inspection of all potentially deleterious calls. 421
For copy number variants, the low throughput of non-NGS-based CNV analysis methods 422 combined with the low prevalence of CNVs makes it difficult to assess CNV calling sensitivity 423 with precision. While in principle orthogonal testing of all negative CNV calls using MLPA, 424
qPCR, or microarrays may uncover additional samples with copy number variants, this would 425 constitute a large discovery effort with low probability of discovering a false negative. The 426 development of a set of reference samples with a diverse deeply-characterized collection of copy 427 number variants (analogous to the efforts of the Genome in a Bottle project) would be a great 428 benefit to laboratory validation procedures. 429
In 
